Immunotherapy for ovarian cancer: what's next?

Détails

Ressource 1Télécharger: zlj925.pdf (367.66 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_5F8A63553AEB
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Immunotherapy for ovarian cancer: what's next?
Périodique
Journal of Clinical Oncology
Auteur(s)
Kandalaft L.E., Powell D.J., Singh N., Coukos G.
ISSN
1527-7755 (Electronic)
ISSN-L
0732-183X
Statut éditorial
Publié
Date de publication
2011
Volume
29
Numéro
7
Pages
925-933
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review Publication Status: ppublish
Résumé
In the past decade, we have witnessed important gains in the treatment of ovarian cancer; however, additional advances are required to reduce mortality. With compelling evidence that ovarian cancers are immunogenic tumors, immunotherapy should be further pursued and optimized. The dramatic advances in laboratory and clinical procedures in cellular immunotherapy, along with the development of powerful immunomodulatory antibodies, create new opportunities in ovarian cancer therapeutics. Herein, we review current progress and future prospects in vaccine and adoptive T-cell therapy development as well as immunomodulatory therapy tools available for immediate clinical testing.
Mots-clé
Aged, Cancer Vaccines/administration & dosage, Disease-Free Survival, Female, Humans, Immunologic Factors/therapeutic use, Immunotherapy/methods, Middle Aged, Ovarian Neoplasms/immunology, Ovarian Neoplasms/mortality, Prognosis, Randomized Controlled Trials as Topic, Risk Assessment, Survival Rate, Treatment Outcome
Pubmed
Web of science
Création de la notice
14/10/2014 11:43
Dernière modification de la notice
20/08/2019 14:17
Données d'usage